Get the Stockscreener App
28.52
0.70%
-0.20
After Hours:
28.55
0.03
+0.11%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $28.52, with a volume of 31.79M.
It is down -0.70% in the last 24 hours and up +2.00% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$28.72
Open:
$28.79
24h Volume:
31.79M
Relative Volume:
0.82
Market Cap:
$162.55B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
21.87
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
+1.21%
1M Performance:
+2.00%
6M Performance:
+2.70%
1Y Performance:
+11.93%
1-Day Range:
$28.52
$28.95
1-Week Range:
$28.17
$28.95
52-Week Range:
$23.62
$29.21
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
28.52 | 163.41B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,157.08 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
264.74 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
261.59 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.31 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.57 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? - Yahoo Finance
Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing? - Yahoo Finance
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside? - Yahoo Finance
Pfizer (PFE) Balances Global Pricing Opportunity with New Revenue Sharing - Yahoo Finance
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. - The Motley Fool
How AI Is Helping Match Patients to Clinical Trials Faster - Pfizer
Pfizer Inc Lobbyists, 2013 - OpenSecrets
Pfizer (NYSE:PFE) Back In Focus As Pricing Deal, Migraine Study, And Vaccine Milestone Shape Its Reset - Kalkine Media
Pfizer (PFE) Bets Big on RSV and Cancer Care - TipRanks
Pfizer: Buy Before The Street Catches Up To Its Own Numbers (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash? - Insider Monkey
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? - Yahoo Finance
Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study - TipRanks
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Pfizer stock reports a Q2 earnings beat at USD 28.43 - AD HOC NEWS
Pfizer stock heads into the open after a 0.82 percent gain - AD HOC NEWS
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth? - Yahoo Finance
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost? - Yahoo Finance
Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans (NYSE:PFE) - Seeking Alpha
Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential - TipRanks
What Is Keeping Pfizer Inc. (NYSE:PFE) in the Healthcare Spotlight This September? - Kalkine Media
Pfizer Says It Removed Affected Batches From Market Amid Karnataka Fake Drug Probe - Medical Dialogues
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? - TradingView
Pfizer stock gains as Q1 profit rises 6.6 percent - AD HOC NEWS
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - theglobeandmail.com
Pfizer Inc. : JP Morgan is Neutral - marketscreener.com
Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks - ChartMill
Pfizer stock heads into the open after a 0.23 percent gain - AD HOC NEWS
Pfizer stock ends the day at USD 27.94 at the close - AD HOC NEWS
PFE Stock Quote Price and Forecast - CNN
Pfizer stock trades at INR 4,025.50 after India drug crackdown - AD HOC NEWS
What Is The Best Case For Pfizer Stock? - Yahoo Finance
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year - Yahoo Finance
Pfizer’s International Chief Just Explained How the Turnaround Actually Works. Here’s Where the Stock Could Go - TIKR.com
Why Is Pfizer (NYSE:PFE) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study - Seeking Alpha
Pfizer Inc. (PFE) stock price, news, quote and history - Yahoo Finance UK
Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? - Yahoo Finance
Pfizer stock holds near USD 28 as new products gain ground - AD HOC NEWS
Can Pfizer (NYSE:PFE) turn pipeline renewal and commercial launches into a stronger market story? - Kalkine Media
Pfizer Inc. stock heads into the open after a 0.23 percent gain - AD HOC NEWS
What Is Keeping Pfizer (NYSE:PFE) in S&P 500 Market Focus Today? - Kalkine Media
Party General Secretary and President visits US pharmaceutical giant Pfizer - VOV.VN
Is Pfizer (PFE) Getting Too Pricey After Its 24% Rise? - simplywall.st
Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade) - Seeking Alpha
Zuckerberg, Bourla among CEOs to attend Trump's state dinner for Xi, sources say - Reuters
Pfizer Inc. - Britannica
Pfizer stock rises 0.23 percent at the close - AD HOC NEWS
Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating (NYSE:PFE) - Seeking Alpha
Pfizer: Stagnant Dividends At Rich YieldsIncome Before Appreciation (NYSE:PFE) - Seeking Alpha
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):